biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Company profile
Ticker
LCTX
Exchange
Website
CEO
Brian Culley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOTIME INC
SEC CIK
Corporate docs
Subsidiaries
Cell Cure Neurosciences Ltd • ES Cell International Pte. Ltd ...
IRS number
943127919
LCTX stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
22 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
S-3
Shelf registration
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
15 Feb 24
424B5
Prospectus supplement for primary offering
6 Feb 24
8-K
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
6 Feb 24
424B5
Prospectus supplement for primary offering
6 Feb 24
S-8
Registration of securities for employees
13 Nov 23
Transcripts
LCTX
Earnings call transcript
2023 Q4
7 Mar 24
LCTX
Earnings call transcript
2023 Q3
9 Nov 23
LCTX
Earnings call transcript
2023 Q2
10 Aug 23
LCTX
Earnings call transcript
2023 Q1
11 May 23
LCTX
Earnings call transcript
2022 Q4
9 Mar 23
LCTX
Earnings call transcript
2022 Q3
11 Nov 22
LCTX
Earnings call transcript
2022 Q2
12 Aug 22
LCTX
Earnings call transcript
2022 Q1
13 May 22
LCTX
Earnings call transcript
2021 Q4
11 Mar 22
LCTX
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.00 mm | 32.00 mm | 32.00 mm | 32.00 mm | 32.00 mm | 32.00 mm |
Cash burn (monthly) | 816.00 k | (no burn) | 2.39 mm | 2.14 mm | 1.68 mm | 2.57 mm |
Cash used (since last report) | 5.63 mm | n/a | 16.45 mm | 14.74 mm | 11.58 mm | 17.73 mm |
Cash remaining | 26.37 mm | n/a | 15.55 mm | 17.26 mm | 20.42 mm | 14.27 mm |
Runway (months of cash) | 32.3 | n/a | 6.5 | 8.1 | 12.2 | 5.6 |
Institutional ownership, Q3 2023
58.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 103 |
Opened positions | 7 |
Closed positions | 8 |
Increased positions | 25 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 87.78 bn |
Total shares | 109.47 mm |
Total puts | 0.00 |
Total calls | 30.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Broadwood Partners | 34.94 mm | $48.91 mm |
Broadwood Capital | 34.94 mm | $41.22 bn |
BLK Blackrock | 9.29 mm | $10.96 bn |
Vanguard | 8.31 mm | $9.81 bn |
Defender Capital | 5.18 mm | $6.12 bn |
Geode Capital Management | 2.77 mm | $3.27 bn |
STT State Street | 2.02 mm | $2.39 bn |
Prescott General Partners | 1.85 mm | $2.19 bn |
Raffles Associates | 1.59 mm | $1.87 bn |
NTRS Northern Trust | 1.20 mm | $1.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Culley Brian M | Employee Stock Option Common Shares | Grant | Acquire A | No | No | 1.13 | 1,900,000 | 2.15 mm | 1,900,000 |
7 Mar 24 | George A. Samuel III | Employee Stock Option Common Shares | Grant | Acquire A | No | No | 1.13 | 650,000 | 734.50 k | 650,000 |
7 Mar 24 | Jill Ann Howe | Employee Stock Option Common Shares | Grant | Acquire A | No | No | 1.13 | 650,000 | 734.50 k | 650,000 |
11 Feb 24 | Culley Brian M | Common Shares, no par value | Payment of exercise | Dispose F | No | No | 1.08 | 12,806 | 13.83 k | 144,842 |
11 Feb 24 | Culley Brian M | Common Shares, no par value | Option exercise | Acquire M | No | No | 0 | 31,249 | 0.00 | 157,648 |
11 Feb 24 | Culley Brian M | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 31,249 | 0.00 | 62,499 |
11 Feb 24 | George A. Samuel III | Common Shares, no par value | Payment of exercise | Dispose F | No | No | 1.08 | 2,490 | 2.69 k | 7,184 |
11 Feb 24 | George A. Samuel III | Common Shares, no par value | Option exercise | Acquire M | No | No | 0 | 6,076 | 0.00 | 9,674 |
11 Feb 24 | George A. Samuel III | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 6,076 | 0.00 | 12,151 |
News
Lineage Cell Therapeutics, Inc. Announces RG6501 (OpRegen) Phase 1/2a Clinical Study 24 Month Results To Be Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
13 Mar 24
Lineage Cell Therapeutics Announces OpRegen Preclinical Engraftment Results To Be Presented At 2024 Association For Research In Vision And Ophthalmology Meeting
11 Mar 24
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
8 Mar 24
Lineage Cell Therapeutics: Q4 Earnings Insights
7 Mar 24
Lineage Cell Therapeutics Q4 2023 GAAP EPS $(0.030) Beats $(0.040) Estimate, Sales $2.100M Beat $1.310M Estimate
7 Mar 24
Press releases
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
13 Mar 24
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
11 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
13 Feb 24
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
9 Feb 24